133 related articles for article (PubMed ID: 10864388)
1. Relationship between Ki-67 labeling index and survival in high-grade glioma patients treated after surgery with tamoxifen.
Mastronardi L; Guiducci A; Puzzilli F; Ruggeri A
J Neurosurg Sci; 1999 Dec; 43(4):263-70. PubMed ID: 10864388
[TBL] [Abstract][Full Text] [Related]
2. Value of MIB-1 labelling index (LI) in gliomas and its correlation with other prognostic factors. A clinicopathologic study.
Rodríguez-Pereira C; Suárez-Peñaranda JM; Vázquez-Salvado M; Sobrido MJ; Abraldes M; Barros F; Forteza J
J Neurosurg Sci; 2000 Dec; 44(4):203-9; discussion 209-10. PubMed ID: 11327289
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas.
Wakimoto H; Aoyagi M; Nakayama T; Nagashima G; Yamamoto S; Tamaki M; Hirakawa K
Cancer; 1996 Jan; 77(2):373-80. PubMed ID: 8625247
[TBL] [Abstract][Full Text] [Related]
4. Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value.
Heesters MA; Koudstaal J; Go KG; Molenaar WM
J Neurooncol; 1999; 44(3):255-66. PubMed ID: 10720205
[TBL] [Abstract][Full Text] [Related]
5. Paradoxical elevation of Ki-67 labeling with protein kinase inhibition in malignant gliomas.
Couldwell WT; Weiss MH; Law RE; Hinton DR
J Neurosurg; 1995 Mar; 82(3):461-8. PubMed ID: 7861225
[TBL] [Abstract][Full Text] [Related]
6. Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort.
Pollack IF; Hamilton RL; Burnham J; Holmes EJ; Finkelstein SD; Sposto R; Yates AJ; Boyett JM; Finlay JL
Neurosurgery; 2002 Jun; 50(6):1238-44; discussion 1244-5. PubMed ID: 12015841
[TBL] [Abstract][Full Text] [Related]
7. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
[TBL] [Abstract][Full Text] [Related]
8. Hypericin uptake: a prognostic marker for survival in high-grade glioma.
Ritz R; Müller M; Dietz K; Duffner F; Bornemann A; Roser F; Tatagiba M
J Clin Neurosci; 2008 Jul; 15(7):778-83. PubMed ID: 18394904
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma.
Abdulrauf SI; Edvardsen K; Ho KL; Yang XY; Rock JP; Rosenblum ML
J Neurosurg; 1998 Mar; 88(3):513-20. PubMed ID: 9488306
[TBL] [Abstract][Full Text] [Related]
10. Expression of cell cycle regulator p27Kip1 is correlated with survival of patients with astrocytoma.
Mizumatsu S; Tamiya T; Ono Y; Abe T; Matsumoto K; Furuta T; Ohmoto T
Clin Cancer Res; 1999 Mar; 5(3):551-7. PubMed ID: 10100706
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic analysis of patients with cerebral glioma treated with radiotherapy].
Wu SX; Deng ML; Li QQ; Zhao C; Lu TX; Li FY; Cui NJ
Ai Zheng; 2004 Nov; 23(11 Suppl):1561-6. PubMed ID: 15566680
[TBL] [Abstract][Full Text] [Related]
12. Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas.
Onda K; Davis RL; Shibuya M; Wilson CB; Hoshino T
Cancer; 1994 Oct; 74(7):1921-6. PubMed ID: 7521787
[TBL] [Abstract][Full Text] [Related]
13. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen and carboplatin combinational treatment of high-grade gliomas. Results of a clinical trial on newly diagnosed patients.
Mastronardi L; Puzzilli F; Couldwell WT; Farah JO; Lunardi P
J Neurooncol; 1998 May; 38(1):59-68. PubMed ID: 9540058
[TBL] [Abstract][Full Text] [Related]
15. [Relationship between miR-218 and CDK6 expression and their biological impact on glioma cell proliferation and apoptosis].
Zhang JM; Sun CY; Yu SZ; Wang Q; An TL; Li YY; Kong YL; Wen YJ
Zhonghua Bing Li Xue Za Zhi; 2011 Jul; 40(7):454-9. PubMed ID: 22088371
[TBL] [Abstract][Full Text] [Related]
16. Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study.
Lunardi P; Osman Farah J; Mastronardi L; Puzzilli F; Lo Bianco FM
Acta Neurochir (Wien); 1996; 138(2):215-20. PubMed ID: 8686548
[TBL] [Abstract][Full Text] [Related]
17. [Individualized therapy and outcomes of microsurgery, radiotherapy, and chemotherapy for astrocytoma].
Zhou WN; Chen ZP; You C; Mu YG; Sai K; Zhang JY; Zhang XH; Cheng JJ; Xu HC
Ai Zheng; 2004 Nov; 23(11 Suppl):1555-60. PubMed ID: 15566679
[TBL] [Abstract][Full Text] [Related]
18. MIB-1 labeling index in nonpilocytic astrocytoma of childhood: a study of 101 cases.
Ho DM; Wong TT; Hsu CY; Ting LT; Chiang H
Cancer; 1998 Jun; 82(12):2459-66. PubMed ID: 9635540
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters.
McKeever PE; Ross DA; Strawderman MS; Brunberg JA; Greenberg HS; Junck L
J Neuropathol Exp Neurol; 1997 Jul; 56(7):798-805. PubMed ID: 9210876
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological features, MIB-1 labeling index and apoptotic index in recurrent astrocytic tumors.
Ralte AM; Sharma MC; Karak AK; Mehta VS; Sarkar C
Pathol Oncol Res; 2001; 7(4):267-78. PubMed ID: 11882906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
